Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib vs GC in Stage IIIA-N2 NSCLC (EMERGING)
NCT01407822Phase 3Unknown
- Sponsor
- Guangdong Association of Clinical Trials
- Start
- Dec 2011
- Primary completion
- Apr 2018
- Countries
- 1
01
Overview
A Phase 3 trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by Guangdong Association of Clinical Trials. Status: unknown.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01407822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01407822.